Niswonger Children's Hospital unveils new clinic
JOHNSON CITY, Tenn. (WJHL) — In addition to a new neonatal transport unit, Niswonger Children's Hospital also unveiled upgrades inside the facility.
Niswonger Radiothon raises $630K for neonatal transport unit
A new clinic has been established on the first floor of the hospital to provide more space for patient care.
Niswonger Children's Hospital cares for children across 29 counties. The hospital offers care in five sub-specialties.
'We've been very grateful to have this and be able to provide this care to our most at-risk kiddos in the region,' Tarah Orcutt, Niswonger Children's Hospital director of operations, said. 'So it's been a really great project, and we're very happy that it's now completed and beautiful.'
Notice dust on your vehicle Friday? Here's where it came from
Orcutt mentioned that the hospital plans to start a smaller-scale construction project on the third floor, specifically for neurology.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Wellness Wednesday: ‘Teddy Bears to the Rescue'
LANSING, Mich. (WLNS) – Cooper Hospital held its annual 'Teddy Bears to the Rescue' event, where teddy bears become the patients and kindergarten students work with medical staff to diagnose and treat them. 'This helps to increase their familiarity to get comfortable with who they might be seeing in the event they ever have to come back. We help to ease their anxiety around coming to the hospital,' Max Kursh with Cooper Hospital explained. Along with prevention lessons, like swimming safety, the students also learned about staying healthy and away from the hospital. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
23 minutes ago
- Yahoo
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, announced today that members of its senior management team will present and participate in the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11th at 10:00 am ET. A live webcast of the presentation can be accessed through the Investors section of the Company's website at Following the live presentation, a replay of the webcast will be available on the Company's website following the presentation date. About Lyell Immunopharma, Inc. Lyell is a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with hematologic malignancies and solid tumors. To realize the potential of cell therapy for cancer, Lyell utilizes a suite of technologies to endow CAR T cells with attributes needed to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical responses, including the ability to resist exhaustion, maintain qualities of durable stemness and function in the hostile tumor microenvironment. To learn more, please visit Contact: Ellen RoseSenior Vice President, Communications and Investor Relationserose@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
35 minutes ago
- Yahoo
BridgeBio Pharma, Inc. (BBIO) Price Target Raised to $56 from $53 at H.C. Wainwright
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the 13 Biotech Stocks with Huge Upside Potential. In a recent report, Raghuram Selvaraju, an expert at H.C. Wainwright, raised the price target for BridgeBio Pharma, Inc. (NASDAQ:BBIO) from $53 to $56 and kept the stock's buy rating. A team of scientists in white lab coats reviewing lab results in a research facility. Positive momentum for the company is proven by the fast uptake of the Attruby product, which is the driving force behind this bullish forecast. For adult patients with ATTR-CM, Attruby is the only nearly full (≥90%) stabilizer of Transthyretin (TTR) that has been approved in the United States to lower cardiovascular mortality and hospitalizations linked to cardiovascular disease. In general, Attruby was highly received. Abdominal pain and diarrhea were the most frequent, moderate side effects that went away without stopping the medication. BridgeBio Pharma, Inc. (NASDAQ:BBIO) provides a wide range of initiatives to facilitate patients' access to our medications. BridgeBio Pharma, Inc. (NASDAQ:BBIO) is a novel biopharmaceutical business that was established to find, develop, test, and distribute revolutionary medications to treat people with hereditary disorders. The development programs in its pipeline span from early science to advanced clinical trials. BBIO is among the stocks with the biggest upside. While we acknowledge the potential of BBIO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data
